Silo pharma announces positive data on spc-15 for ptsd and prepares to file pre-investigational new drug (ind) application with fda

Pre-ind submission to fda targeted for first quarter 2024 silo partners with kymanox for spc-15 englewood cliffs, nj, sept. 20, 2023 (globe newswire) -- silo pharma, inc. (nasdaq: silo) (“the company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that based on positive spc-15 pre-clinical data, it is working with kymanox as its regulatory partner to assist with the preparation of a pre-investigational new drug (ind) package and meeting request with the united states food and drug administration (fda).
SILO Ratings Summary
SILO Quant Ranking